Emily J. Pomeroy

1.1k total citations
20 papers, 688 citations indexed

About

Emily J. Pomeroy is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Emily J. Pomeroy has authored 20 papers receiving a total of 688 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Emily J. Pomeroy's work include CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (7 papers) and CRISPR and Genetic Engineering (5 papers). Emily J. Pomeroy is often cited by papers focused on CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (7 papers) and CRISPR and Genetic Engineering (5 papers). Emily J. Pomeroy collaborates with scholars based in United States, United Kingdom and Canada. Emily J. Pomeroy's co-authors include Branden S. Moriarity, Beau R. Webber, Walker S. Lahr, Branden A. Smeester, Mitchell G. Kluesner, Cara-lin Lonetree, Nicholas J. Slipek, Kenta Yamamoto, Craig E. Eckfeldt and Wendy R. Gordon and has published in prestigious journals such as Nature Communications, Blood and The Journal of Immunology.

In The Last Decade

Emily J. Pomeroy

20 papers receiving 675 citations

Peers

Countries citing papers authored by Emily J. Pomeroy

Since Specialization

Citations

This map shows the geographic impact of Emily J. Pomeroy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily J. Pomeroy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily J. Pomeroy more than expected).

Fields of papers citing papers by Emily J. Pomeroy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily J. Pomeroy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily J. Pomeroy. The network helps show where Emily J. Pomeroy may publish in the future.

Co-authorship network of co-authors of Emily J. Pomeroy

This figure shows the co-authorship network connecting the top 25 collaborators of Emily J. Pomeroy. A scholar is included among the top collaborators of Emily J. Pomeroy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily J. Pomeroy. Emily J. Pomeroy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Mitchell G. Kluesner, Emily J. Pomeroy, Joseph G. Skeate, Nicholas J. Slipek, Walker S. Lahr, (unknown), (unknown), Jason Bell, Kendell Clement, (unknown), Kanut Laoharawee, (unknown), Beau R. Webber, Branden S. Moriarity	8
2	Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine Production 2023 ·The Journal of Immunology ·(unknown), (unknown), Jules Sangala, Philippa R Kennedy, Emily J. Pomeroy, Kristin M. Snyder, (unknown), (unknown), Jianming Wu, Sara E. Hamilton, Martin Felices, Jeffrey S. Miller, Bruce Walcheck, Beau R. Webber, Branden S. Moriarity, Geoffrey T. Hart	6
3	Multiplex Prime Editing and PASSIGE TM for Non-Viral Generation of an Allogeneic CAR-T Cell Product 2023 ·Blood ·Emily J. Pomeroy, Andrew V. Anzalone, (unknown), (unknown), (unknown), (unknown), Kanut Laoharawee, Alan Wilhelm, David P. Waterman, (unknown), (unknown), Elizabeth R. Macari, Jennifer L. Gori, Jeremy S. Duffield	7
4	392 Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies 2022 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), Joseph G. Skeate, (unknown), Walker S. Lahr, Nicholas J. Slipek, Emily J. Pomeroy, Meghan T. Walsh, Jennifer Johnson, (unknown), Simarjot Pabla, Jared Allan Sewell, (unknown), Vipin Suri, Beau R. Webber, Branden S. Moriarity	1
5	Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments 2021 ·Nature Communications ·Erdem D. Tabdanov, (unknown), Alexander X. Cartagena‐Rivera, (unknown), (unknown), (unknown), Emily J. Pomeroy, Kenta Yamamoto, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Alexander S. Zhovmer, Paolo P. Provenzano	90
6	CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells 2021 ·Nature Communications ·Mitchell G. Kluesner, Walker S. Lahr, Cara-lin Lonetree, Branden A. Smeester, Xiaohong Qiu, Nicholas J. Slipek, (unknown), (unknown), Emily J. Pomeroy, (unknown), (unknown), (unknown), (unknown), Beau R. Webber, Branden S. Moriarity	74
7	Nonviral genome engineering of natural killer cells 2021 ·Stem Cell Research & Therapy ·(unknown), (unknown), Emily J. Pomeroy, Branden S. Moriarity	30
8	Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies 2021 ·Blood ·Eugene Choi, (unknown), (unknown), Walker S. Lahr, Emily J. Pomeroy, (unknown), (unknown), Jennifer Johnson, (unknown), Lukasz Swiech, Simarjot Pabla, Celeste Richardson, Vipin Suri, Beau R. Webber, Branden S. Moriarity	20
9	Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma 2020 ·Molecular Cancer Therapeutics ·Branden A. Smeester, (unknown), Nicholas J. Slipek, (unknown), Natalie Stratton, Emily J. Pomeroy, (unknown), Kenta Yamamoto, Kyle Williams, Kanut Laoharawee, (unknown), Juan E. Abrahante, Susan K. Rathe, Lauren J. Mills, (unknown), Wendy A. Hudson, Eric P. Rahrmann, David A. Largaespada, Branden S. Moriarity	13
10	Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity 2020 ·Seminars in Hematology ·Meisam Naeimi Kararoudi, Brian P. Tullius, Nitin Chakravarti, Emily J. Pomeroy, Branden S. Moriarity, Kathie Béland, (unknown), Élie Haddad, Yaya Chu, Mitchell S. Cairo, Dean A. Lee	17
11	PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma 2020 ·Bone ·Branden A. Smeester, Nicholas J. Slipek, Emily J. Pomeroy, Kanut Laoharawee, (unknown), (unknown), Kyle Williams, Natalie Stratton, Kenta Yamamoto, (unknown), Susan K. Rathe, Lauren J. Mills, Wendy A. Hudson, (unknown), (unknown), Eric P. Rahrmann, Branden S. Moriarity, David A. Largaespada	28
12	A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy 2019 ·Molecular Therapy ·Emily J. Pomeroy, John Hunzeker, Mitchell G. Kluesner, Walker S. Lahr, Branden A. Smeester, (unknown), Cara-lin Lonetree, Kenta Yamamoto, Laura E. Bendzick, Jeffrey S. Miller, Melissa A. Geller, Bruce Walcheck, Martin Felices, Beau R. Webber, Timothy K. Starr, Branden S. Moriarity	139
13	SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis 2019 ·Oncogene ·Branden A. Smeester, Nicholas J. Slipek, Emily J. Pomeroy, (unknown), Ghaidan A. Shamsan, (unknown), (unknown), (unknown), (unknown), Eric P. Rahrmann, James B. McCarthy, David J. Odde, David K. Wood, David A. Largaespada, Branden S. Moriarity	12
14	Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors 2019 ·Nature Communications ·Beau R. Webber, Cara-lin Lonetree, Mitchell G. Kluesner, Matthew J. Johnson, Emily J. Pomeroy, Miechaleen D. Diers, Walker S. Lahr, (unknown), Nicholas J. Slipek, Branden A. Smeester, Klaus N. Lovendahl, Amber McElroy, Wendy R. Gordon, Mark J. Osborn, Branden S. Moriarity	155
15	An Indole–Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules 2018 ·Molecular Pharmaceutics ·Hui Cong, Xinghua Zhao, Brian T. Castle, Emily J. Pomeroy, Bo Zhou, J. Jack Lee, Yi Wang, Tengfei Bian, Zhenyuan Miao, Wannian Zhang, Yuk Y. Sham, David J. Odde, Craig E. Eckfeldt, Chengguo Xing, Chunlin Zhuang	46
16	Targeting Ras signaling in AML: RALB is a small GTPase with big potential 2017 ·Small GTPases ·Emily J. Pomeroy, Craig E. Eckfeldt	12
17	Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency 2016 ·Haematologica ·Zohar Sachs, (unknown), (unknown), Hoa Nguyen, (unknown), (unknown), Craig E. Eckfeldt, Emily J. Pomeroy, Ernesto Díaz-Flores, Jennifer L. Geurts, (unknown), Diane E. Hasz, Kelly Morgan, Margaret L. MacMillan, Kevin Shannon, (unknown), Stephen M. Wiesner	12
18	Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia 2016 ·Oncogene ·Emily J. Pomeroy, (unknown), (unknown), Dawn K. Schirm, Nuri A. Temiz, Jing Ma, Tanja A. Grüber, Ernesto Díaz-Flores, Branden S. Moriarity, James R. Downing, Kevin Shannon, David A. Largaespada, Craig E. Eckfeldt	10
19	RALB provides critical survival signals downstream of Ras in acute myeloid leukemia 2016 ·Oncotarget ·Craig E. Eckfeldt, Emily J. Pomeroy, (unknown), (unknown), (unknown), Branden S. Moriarity, David A. Largaespada	7
20	The role of muscle-synthesized brain-derived neurotrophic factor (BDNF) in the health and maintenance of motorneurons 2013 ·Emily J. Pomeroy	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact